

Visual Performance of Clareon PanOptix vs. a Comparable Multifocal Intraocular Lens

NCT07006428

Status	RECRUITING
Phase	Not Applicable
Sponsor	Argus Research Center, Inc.
Enrollment	290 participants

Key Eligibility Criteria

Inclusion (13)

- Stage 1: IIT Pilot
 - Willing and able to understand and sign informed consent.
 - Adult patients previously diagnosed with age-related cataracts bilaterally.
 - Previous bilateral age-related cataract removal and with bilateral implantation of the Clareon PanOptix/ Clareon PanOptix Toric (T3-T4) or Comparable Multifocal Intraocular Lens (equivalent to T3-T4) closest to 2.5-5-months after implantation and ≥ 2 weeks post YAG (if done) that were targeted for emmetropia.
 - Best monocular corrected distance visual acuity was expected to be 0.1 logMAR (Snellen 20/25) or better in both eyes pre-operatively as determined by surgeon.
- ... and 8 more (see full listing online)

Exclusion (16)

- Stage 1: IIT Pilot
 - Corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases, diabetic retinopathy that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation.
 - Previous history of any ocular surgery including corneal refractive surgery.
 - Participation in another clinical study that could interfere with the results.
 - Patients with monovision correction.
- ... and 11 more (see full listing online)

Locations (3 total)

Wolstan & Goldberg Eye Associates, Torrance, California, United States
Tyson Eye, Cape Coral, Florida, United States
North Georgia Eye Associates, Gainesville, Georgia, United States